Late-Onset Retinal Degeneration Treatments

Find Late-Onset Retinal Degeneration Treatments

Generic Name

Aflibercept

Brand Names
Pavblu, Eylea, Zaltrap
FDA approval date: November 21, 2011
Classification: Vascular Endothelial Growth Factor Inhibitor
Form: Injection, Solution

What is Pavblu (Aflibercept)?

EYLEA HD is indicated for the treatment of: EYLEA HD is a vascular endothelial growth factor inhibitor indicated for the treatment of patients with: Neovascular Age-Related Macular Degeneration .
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances

Related Clinical Trials

A Randomized Double-masked, Multicenter, 3-arm, Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) EYE201/MK-8748 Compared to Aflibercept (2 mg) in Participants With Neovascular Age-related Macular Degeneration (NVAMD)

Summary: Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD. The goal of this trial is to learn if tiespectus works as well as aflibercept to treat...

Intra Ocular Pressure Monitoring After Intravitreal Injection of Aflibercept 8mg/0.07mL

Summary: In just a few years, intravitreal injections have become a standard method of administration for certain retinal deseases (age-related macular degeneration \[AMD\], diabetic edematous maculopathy or retinal vein occlusion \[RVO\]). Thus, vascular endothelial growth factor (anti-VEGF) inhibitors are injected repetitively, every 4 to 6 weeks, in some patients in order to treat such pathologies. It i...

Brand Information